NCT03514121: FPA150 in Patients With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Early Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 99 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: Restrictions on the number of lines of previous treatment- see trial for details
Exclusions: HER2+ patients are not eligible for the dose expansion (Phase 1b); Patients with untreated or active CNS or leptomeningeal metastases- see trial for details

Comments are closed.

Up ↑